🟢 Rezolute is trading 5.77% up today in pre-market as FDA continues reviewing Phase 3 sunRIZE data

Rezolute is trading at $4.29, up 5.77% in pre-market after its September 9, 2026 update that the FDA continues reviewing Phase 3 sunRIZE data.

• The study missed its primary and key secondary endpoints.
• Rezolute highlighted favorable CGM-based results and potential evidence of glycemic improvement.
• The FDA provided no specific timeline for feedback, leaving the stock volatile ahead of further regulatory clarity.